Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Balixafortide,Eribulin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Balixafortide (POL6326) is a potent, specific, and highly selective antagonist of the chemokine receptor CXCR4, a G-protein coupled receptor (GPCR) that regulates the trafficking and homing of both cancer cells and cells of the patient’s immune system.
Product Name : POL6326
Product Type : Peptide
Upfront Cash : Inapplicable
June 28, 2021
Lead Product(s) : Balixafortide,Eribulin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Balixafortide,Eribulin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The study confirmed the positive safety and tolerability profile of balixafortide in line with the previously reported Phase Ib study.
Product Name : POL6326
Product Type : Peptide
Upfront Cash : Inapplicable
June 28, 2021
Lead Product(s) : Balixafortide,Eribulin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Balixafortide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Balixafortide is a potent, selective CXCR4 antagonist which is currently also in Phase III development in combination with eribulin in patients with metastatic HER-2 negative breast cancer.
Product Name : POL6326
Product Type : Peptide
Upfront Cash : Inapplicable
January 06, 2021
Lead Product(s) : Balixafortide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Murepavadin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Polyphor Receives Approval to Start First-in-Human Clinical Trial of Inhaled Antibiotic Murepavadin
Details : The phase I study will evaluate the safety and tolerability of single and multiple ascending doses of inhaled murepavadin in healthy volunteers and will be jointly funded by Polyphor and the European Innovative Medicines Initiative (IMI).
Product Name : POL7080
Product Type : Peptide
Upfront Cash : Inapplicable
December 22, 2020
Lead Product(s) : Murepavadin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Murepavadin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Cystic Fibrosis Foundation
Deal Size : $3.3 million
Deal Type : Funding
Details : Award will help to fund planned Phase Ib/IIa study of inhaled murepavadin, a novel class antibiotic for the treatment of chronic Pseudomonas aeruginosa infections in cystic fibrosis.
Product Name : POL7080
Product Type : Peptide
Upfront Cash : Undisclosed
November 24, 2020
Lead Product(s) : Murepavadin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Cystic Fibrosis Foundation
Deal Size : $3.3 million
Deal Type : Funding
Lead Product(s) : Balixafortide,Eribulin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Polyphor Completes Recruitment in Phase III Trial of Balixafortide in Metastatic Breast Cancer
Details : The FORTRESS study is an international, multicenter, randomized active-controlled, open-label Phase III trial which investigates the efficacy, safety and tolerability of intravenous balixafortide given with eribulin vs eribulin alone to treat metastatic ...
Product Name : POL6326
Product Type : Peptide
Upfront Cash : Inapplicable
October 29, 2020
Lead Product(s) : Balixafortide,Eribulin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Thanatin-Derivative Antibiotic
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : CARB-X
Deal Size : $18.4 million
Deal Type : Funding
Details : Award will support the development of the “thanatin derivatives program” belonging to Polyphor’s novel Outer Membrane Protein Targeting Antibiotic (OMPTA) class of antibiotics to potentially treat life-threatening infections caused by difficult-to-...
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Undisclosed
October 14, 2020
Lead Product(s) : Thanatin-Derivative Antibiotic
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : CARB-X
Deal Size : $18.4 million
Deal Type : Funding
Lead Product(s) : Balixafortide,Eribulin
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Polyphor announces progress of the Phase III immuno-oncology program with balixafortide
Details : If successful, balixafortide will be the first in class CXCR4 antagonist approved for a solid tumor indication widening the opportunities in the field of immuno-oncology.
Product Name : POL6326
Product Type : Peptide
Upfront Cash : Inapplicable
February 20, 2020
Lead Product(s) : Balixafortide,Eribulin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable